抗瘤升白超微饮片治疗白细胞减少症的临床观察及药物经济学分析(1)
 |
| 第1页 |
参见附件(1849KB，3页)。
[摘要] 目的：对比观察抗瘤升白超微饮片、传统汤剂及片剂治疗恶性肿瘤化疗所致骨髓损伤的疗效及药物经济学差异。方法：将90例化疗后出现白细胞减少症的患者随机分为抗瘤升白超微饮片组(超微组)、抗瘤升白片剂组(片剂组)和抗瘤升白汤剂组(汤剂组)。其中片剂组和汤剂组药物剂量相等，超微组剂量为汤剂、片剂剂量的1/2，各组均口服给药，连续给药4周，观察3组白细胞逐周变化、治疗白细胞减少症疗效、显效时间、生存质量，采用成本-效果分析法比较各组药物经济学性能。结果：在进行4周治疗后，超微组与片剂组、汤剂组白细胞数均较治疗前升高，差异有统计学意义(P<0.01)，各组间白细胞逐周变化差异无统计学意义(P>0.05)。超微组、片剂组、汤剂组治疗白细胞减少症的总有效率分别为86.7%、80.0%、83.3%，差异无统计学意义(P>0.05)。超微组显效时间为(13.2±1.5) d，较片剂组、汤剂组短，差异有统计学意义(P<0.05)。生存质量比较，3组差异无统计学意义(P>0.05)。超微组、片剂组、汤剂组成本效果比分别为4.55、4.62、4.37，3组比值接近。结论：抗瘤升白超微饮片在治疗白细胞减少症及改善患者生活质量方面与抗瘤升白片及抗瘤升白传统汤药疗效相同，不增加治疗成本，起效更快。
[关键词] 抗瘤升白片；超微饮片；白细胞减少症；药物经济学
[中图分类号] R557+.1[文献标识码]A [文章编号]1673-7210(2009)05(c)-015-03
Clinical observation and pharmacoeconomics analysis on treating leucopenia with Kangliu Shengbai Ultramicro Granule
ZENG Bairong1, GUO Zhongcong2#, CAI Guangxian2, HE Xin1
(1.Department of Oncology, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410007, China; 2.Hunan University of Chinese Medicine, Changsha 410208, China)
[Abstract] Objective: To study the difference of clinical efficacy and pharmacoeconomics on treating leucopenia with Kangliu Shengbai Ultramicro Granule, Tablet and traditional decoction group. Methods: 90 patients with leucopenia after chemotherapy were randomly divided into Ultramicro Granule group, Tablet group and traditional decoction group. All patients were respectively given Kangliu Shengbai Ultramicro Granule, Tablet and traditional decoction orally for 4 weeks. The change of leucocyte week by week, the clinical efficiency of leucopenia, the time of complete healing and the change of living quality were observed. The pharmacoeconomics among three groups were evaluated by the cost-effectiveness methods. Results: The count of leucocyte of all patients in three groups were higher after treatment, the difference was significant (P<0 ......
您现在查看是摘要介绍页，详见PDF附件(1849KB，3页)。